Clinical Trial News and Research

RSS

Invision Sally Jobe introduces SBU technology for early detection of breast cancer

Invision Sally Jobe is among the first diagnostic imaging networks in the nation to offer a new breast ultrasound technology for the early detection of cancer. Screening Breast Ultrasound is a highly effective technology developed to complement mammography in women with radiologically dense breasts and other risk factors.

7 Jul 2010

Capstone Therapeutics to continue AZX100 Phase 2a trial in dermal scarring to planned 12-month endpoints

Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from its ongoing AZX100 Phase 2a clinical trial in trocar site scarring following arthroscopic shoulder surgery. Based on this analysis, the clinical trial will continue to its planned 12-month endpoints.

7 Jul 2010

Aastrom to pursue Phase 3 CLI clinical program through FDA SPA process

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the company will pursue a Phase 3 clinical program for its autologous cell therapy for the treatment of critical limb ischemia (CLI) through the U.S. Food and Drug Administration's special protocol assessment (SPA) process. Aastrom is currently completing a Phase 2b clinical trial of its cell therapy in patients with CLI and recently met with FDA officials to discuss plans for the Phase 3 program.

7 Jul 2010

Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis

Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.

7 Jul 2010

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.

7 Jul 2010

Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed

Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.

7 Jul 2010

Three Rivers Pharmaceuticals receives FDA expanded labeling for INFERGEN

Three Rivers Pharmaceuticals, LLC, today received expanded labeling from the U.S. Food and Drug Administration (FDA) to include daily use of INFERGEN (Consensus Interferon) in combination with ribavirin (RBV) for retreatment of chronic hepatitis C patients. The expanded labeling targets hepatitis C patients who need retreatment.

6 Jul 2010

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study

Adeona Pharmaceuticals, Inc., announced today that on July 6, 2010, it completed an equity financing of $1 million with a single institutional investor, Seaside 88, L.P. The financing involved the sale of 1,212,121 registered shares of common stock and no warrants. Enclave Capital served as placement agent and will receive a 7% cash commission and 5-year warrants to acquire 60,606 shares of Adeona at $1.32 per share. The use of proceeds is intended for general corporate purposes.

6 Jul 2010

Nottingham researchers undertake new clinical trial on hearing loss

Researchers at The University of Nottingham are embarking on a clinical trial that will help them to further understand the debilitating condition of hearing loss.

6 Jul 2010

EC approves change in posology of Circadin from 3 weeks to 3 months of treatment

Neurim Pharmaceuticals confirmed today that the European Commission (EC) has approved a change in treatment duration with Circadin from 3 to 13 weeks (3 months). Circadin is indicated for the treatment of primary insomnia in patients who are aged 55 or over.

6 Jul 2010

Synexus expands clinical trial operations in Gydnia, Poland

Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials is expanding its operations in Gydnia, Poland when it moves to new premises later this year. It has also recently increased the capacity of its original centre in Wroclaw by several hundred square metres.

From AES - Accelerated Enrollment Solutions 5 Jul 2010

Abbott’s plans to aid diabetes research if elected

Opposition Leader Tony Abbott announced last Saturday that he would be rolling out a $35 million funding for a clinical trial network (CTN) to improve the health of Australians with diabetes if he is elected as Prime Minister. The Rudd Governments $5million to the CTN will be supplemented by these funds. “This is one Coalition commitment I would be very happy for the government to match,” he said.

4 Jul 2010

Recent releases in global health

Looking ahead to AIDS 2010 which will be held in Vienna, Austria, July 18-23, a Lancet editorial writes that 2010 marks "the deadline set by global leaders to achieve universal access to HIV prevention, treatment, and care. Sadly, the world will not meet these ambitious goals." However, the latest issue of the Lancet "offers some new insights to progress," the editorial notes.

3 Jul 2010

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Neogenix Oncology announced today that the company has filed a patent application with the U.S. Patent and Trade Office (USPTO) for the 16C3 antigen. The Company believes that this antigen is tumor specific for pancreatic and colorectal tumors; and, based on preliminary clinical data, may also have diagnostic utility as a biomarker for these cancers.

3 Jul 2010

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

2 Jul 2010

Investment report on Arena Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Arena Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

2 Jul 2010

Biomimetic Therapeutics to discuss Augment Bone Graft data results at AOFAS meeting

BioMimetic Therapeutics, Inc. today announced its schedule of events at the American Orthopaedic Foot and Ankle Society (AOFAS) summer meeting being held at the Gaylord National Hotel and Convention Center in National Harbor, Maryland from July 7 - 10, 2010.

2 Jul 2010

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

1 Jul 2010

Studies on VIAject and Vialog presented at 70th American Diabetes Association sessions

Studies of a more-rapid-acting injectable human insulin formulation (VIAject®) in the treatment of type 1 and type 2 diabetes and of a novel insulin analog formulation (Vialog™) in an animal model of diabetes were reported this week in three poster presentations at the 70th Scientific Sessions of the American Diabetes Association in Orlando, Florida. The findings are based upon results from recent clinical and preclinical studies sponsored by Biodel Inc..

1 Jul 2010

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.

1 Jul 2010

Clinical Trial News and Research

Invision Sally Jobe introduces SBU technology for early detection of breast cancer

Capstone Therapeutics to continue AZX100 Phase 2a trial in dermal scarring to planned 12-month endpoints

Aastrom to pursue Phase 3 CLI clinical program through FDA SPA process

Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed

Three Rivers Pharmaceuticals receives FDA expanded labeling for INFERGEN

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study

Nottingham researchers undertake new clinical trial on hearing loss

EC approves change in posology of Circadin from 3 weeks to 3 months of treatment

Synexus expands clinical trial operations in Gydnia, Poland

Abbott’s plans to aid diabetes research if elected

Recent releases in global health

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Investment report on Arena Pharmaceuticals

Biomimetic Therapeutics to discuss Augment Bone Graft data results at AOFAS meeting

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Studies on VIAject and Vialog presented at 70th American Diabetes Association sessions

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News